Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 33

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 33
---
 such movements. Our exchange rate exposure
may change over time as our business evolves and could result in increased costs or reduced revenue and could affect our actual cash
flow. Changes in the relative values of currencies occur regularly and, in some instances, may have a significant impact on our operating
results. The rate of inflation in Israel or in currency exchange rates may materially change and we might not be able to effectively
mitigate these risks.

The outcome of any future claims and litigation could have a material adverse impact on our business, financial condition and results of operations.

We may, from time to time,
be party to litigation in the normal course of business, including class action lawsuits. Due to the inherent uncertainties of litigation,
the final outcome of these lawsuits may differ substantially from our expectations and we may not be able to determine the amount of
any potential losses we may incur. In the event we are required or determine to pay amounts in connection with any such lawsuits, such
amounts could be significant and could have a material adverse impact on our liquidity, business, financial condition and results of
operations.

<div align='center'>24</div>

Certain of our directors, director nominees and/or officers may have interests that compete with ours and our shareholders.

Certain of our directors
currently own, operate and manage other entities, which may have similar or different objectives than ours. Such activities could detract
from the time these people have to allocate to our affairs. The terms of such agreements may not be as favorable to us as those that
could be obtained from a third party. Moreover, certain of our directors and officers are affiliated with our current shareholders, and
may have different interests than other shareholders. For additional information regarding related party transactions and potential conflicts
of interest, see “Certain Relationships and Related Party Transactions.” Under the Israeli Companies Law, 5759-1999, or the
Companies Law, office holders must promptly disclose to us any direct or indirect personal interest that he or she may have and all related
material information or documents known to him or her relating to any existing or proposed transaction by us. See “Fiduciary Duties
and Approval of Specified Related Party Transactions and Compensation Under Israeli Law—Disclosure of Personal Interests of an
Office Holder and Approval of Certain Transactions.” In addition, on the closing of this offering, we will adopt a code of ethics
and conduct that will require our employees, officers and directors to disclose any situation that reasonably would be expected to give
rise to a conflict of